Crestline Investors, Inc., 10% Owner at Juno Therapeutics, Inc. (JUNO), sold 8,000,000 shares at $27.00 ($216.0M) on 2017-07-13, disclosed to the SEC on 2017-07-17.
Open-market sale of $216.0M JUNO by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| Filing → |
| JUNO | SELL | 2016-03-03 | $335.4M | — | Filing → |